Management Team

Halvor Jaeger M.D., F.C.P
CEO, AKELA Pharma Inc.

After receiving an M.D. degree from the University of Ulm in Germany in 1976, Dr. Jaeger started a scientific career at this University. In 1979, he founded LAB in Germany and as its CEO developed it as of one of the principal contract research institutes in Germany. In addition he lectured pharmacology for several years. After selling LAB Germany in 1995 to a worldwide provider of pharmaceutical services, he relocated to Canada and took over LAB International Canada. After substantial increase in value, the PhaseI/Bioanalytical business of the company was sold to a Toronto based public company in 1998, and the pharmaceutical arm to a French company. At that time LAB Pre-clinical was founded as a new company and taken public in 2002 as a Product Development Company. The aim of the company is to develop products with substantial funds being generated through its service business.

Dr. Jaeger has written and/or collaborated on over one hundred scientific publications. He acted as Expert Agréé for the French Health Authorities in pharmacokinetics. In 1996, he was appointed Fellow of the American College of Clinical Pharmacology.


Andrew Reiter
CFO/COO – AKELA Pharma Inc.

Mr. Reiter is an accomplished senior financial executive with extensive experience in publicly traded corporations. Mr. Reiter is currently CFO of AKELA Pharma Inc. “AKELA”, a fully integrated drug-development company listed on the Toronto Stock Exchange (TSX:AKL).
During his career, Mr. Reiter has held various executive financial positions for private and public companies, including Silonex Inc. where he acted as the Chief Financial Officer, SR Telecom as the Director of Finance / Corporate Controller, The Yellow Pages Group as the Corporate Controller, Dicom Express Inc. as the Vice-President, Finance & Administration and Deloitte & Touche where he was a Senior Manager. Mr. Reiter holds a C.A. designation with a Diploma in Public Accountancy from McGill University and a Bachelor of Commerce from Concordia University.
Over the last 10 years Mr. Reiter has been involved in numerous financings and investment rounds.

Taneli Jouhikainen, M.D., Ph.D., MBA
Senior Vice President, Corporate Development

Dr. Jouhikainen is a veteran executive with an impressive career in the medical and pharmaceutical industry. Since 1996 Dr. Jouhikainen has occupied management positions with increasing responsibilities.
Dr. Jouhikainen is currently Senior Vice President Corporate Development of AKELA Pharma Inc. During his career, Dr. Jouhikainen has held executive positions for various companies including President and CEO for Focus Inhalation Oy, Vice-President, Business Development & Strategy for Focus Inhalation Oy, Chairman of the Board for Spectrum Medical Sciences and Director, Clinical Research, Leiras Oy, Research & Development. Dr. Jouhikainen is a licentiate of Medicine, Doctor of Medical Sciences and MBA.
Dr. Jouhikainen is also a published author in scientific publications in peer- reviewed scientific journals. 

J. Bossart Senior Vice President Business Development

Dr. Josef Bossart is Senior Vice President of Business Development for AKELA Pharma.  Prior to joining AKELA in 2007, Jo held a variety of sales, marketing, general management and business development positions during his more than twenty-five year tenure within the biopharmaceutical industry.  Most recently he was the founder of B4Bio, a business and corporate development services company.  His earlier biopharmaceutical company experience includes vice president level business development positions with Enzon Pharmaceuticals, GeneMedicine and the Rhône-Poulenc Rorer group.  Jo earned his Ph.D. in Medicinal Chemistry from the Ohio State University, College of Pharmacy.  He regularly contributes industry articles in the area of drug delivery, specialty pharma and biotechnology.

Frédéric Dumais
Vice President Investor Relations – AKELA Pharma Inc.

Mr. Dumais is a seasoned executive with experience in communications, business development and the legal industry. Since 1998 Mr. Dumais has also developed extensive experience in the investor relations and corporate communication sectors.
Mr. Dumais is currently the Vice President Investor Relations of AKELA Pharma Inc. During his career, Mr. Dumais has held management positions in various companies and industries. Prior to joining LAB International, Mr. Dumais was the Sales Manager, Corporate accounts for CNW Telbec, the leading firm in corporate disclosure services, Group Sales Manager for Future Electronics and Sales supervisor for Coca-Cola Bottling amongst others. Mr. Dumais holds a Bachelor of Commerce and Law degree and is a member of the Barreau du Québec.